Hikma maintains its 2016 interim dividend at last years level

DividendMax Ltd.

Hikma maintains its 2016 interim dividend at last years level

Group revenue of $882 million, up 24% in H1 2016 and up 28% in constant currency5

Completed West-Ward Columbus acquisition, making significant progress with integration and on track to deliver cost synergies 

Group core operating profit of $176 million, down 14% and down 3% in constant currency, due to a lower contribution from specific market opportunities for the Generics business compared with the first half of 2015

Group core basic earnings per share of 48.2 cents, down 32% and down 21% in constant currency

Launched 44 products and received 182 approvals, expanding and enhancing our global product portfolio

Launched 3 Bedford products in the year to-date and on track to achieve our target of 20 Bedford launches by the end of 2017

Interim dividend of 11.0 cents per share, in line with the interim dividend for H1 2015

The guidance published in the trading update on 3 August 2016 is unchanged

Continue to expect 2016 Group revenue in the range of $2.0 billion to $2.1 billion in constant currency, driven by strong growth in Injectables and Branded and the consolidation of ten months of revenue from West-Ward Columbus

Companies mentioned